Endoscopic management of gastrointestinal stromal tumors

被引：25

作者：

Chandrasekhara V. ^{[1
]}

Ginsberg G.G. ^{[1
]}

机构：

[1] Hospital of the University of Pennsylvania, GI Division, Philadelphia, PA 19104, 3 Ravdin

来源：

Current Gastroenterology Reports | 2011年 / 13卷 / 6期

关键词：

Endoscopy; Gastrointestinal stromal tumors; GIST; Subepithelial mass; Subepithelial tumor; Submucosal mass; Submucosal tumor;

D O I：

10.1007/s11894-011-0224-6

中图分类号：

学科分类号：

摘要：

Subepithelial lesions are increasingly being identified with improved endoscopic imaging technologies. Many of these lesions are now recognized as gastrointestinal stromal tumors (GISTs). Recent advances in immunohistochemistry have allowed for reliable differentiation of GISTs from other subepithelial tumors, thereby significantly improving our understanding of these lesions. The wealth of recent information and continual evolution in our understanding of GISTs has exposed some knowledge gaps pertaining to the optimal management of these lesions. In this article, we review the endoscopic management of GISTs as it relates to the identification, diagnosis and management of these lesions based on the best available literature and our own clinical experience to date. © 2011 Springer Science+Business Media, LLC.

引用

页码：532 / 539

页数：7

共 54 条

[1]

Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M., Tunio G.M., Matsuzawa Y., Kanakura Y., Shinomura Y., Kitamura Y., Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors, Science, 279, 5350, pp. 577-580, (1998)

[2]

Miettinen M., Lasota J., Gastrointestinal stromal tumors: Pathology and prognosis at different sites, Seminars in Diagnostic Pathology, 23, 2, pp. 70-83, (2006)

[3]

Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.-J., Joseph N., Singer S., Griffith D.J., Haley A., Town A., Demetri G.D., Fletcher C.D.M., Fletcher J.A., PDGFRA activating mutations in gastrointestinal stromal tumors, Science, 299, 5607, pp. 708-710, (2003)

[4]

Lee C.H., Liang C.W., Espinosa I., The utility of discovered on gastrointestinal stromal tumor 1 (DOG1) antibody in surgical pathology - The GIST of it, Adv Anat Pathol, 17, pp. 222-232, (2010)

[5]

Novelli M., Rossi S., Rodriguez-Justo M., Et al., DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours, Histopathology, 57, pp. 259-270, (2010)

[6]

Ho M.Y., Blanke C.D., Gastrointestinal stromal tumors: Disease and treatment update, Gastroenterology, 140, pp. 1372-1376, (2011)

[7]

Nilsson B., Bumming P., Meis-Kindblom J.M., Oden A., Dortok A., Gustavsson B., Sablinska K., Kindblom L.-G., Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - A population-based study in western Sweden, Cancer, 103, 4, pp. 821-829, (2005)

[8]

Tryggvason G., Gislason H.G., Magnusson M.K., Jonasson J.G., Gastrointestinal stromal tumors in Iceland, 1990-2003: The Icelandic GIST study, a population-based incidence and pathologic risk stratification study, International Journal of Cancer, 117, 2, pp. 289-293, (2005)

[9]

Tryggvason G., Kristmundsson P., Orvar K., Jonasson J.G., Magnusson M.K., Gislason H.G., Clinical study on gastrointestinal stromal tumors (GIST) in Iceland, 1990-2003, Digestive Diseases and Sciences, 52, 9, pp. 2249-2253, (2007)

[10]

Agaimy A., Wunsch P.H., Hofstaedter F., Blaszyk H., Rummele P., Gaumann A., Dietmaier W., Hartmann A., Minute Gastric Sclerosing Stromal Tumors (GIST Tumorlets) are common in adults and frequently show c-KIT mutations, American Journal of Surgical Pathology, 31, 1, pp. 113-120, (2007)

← 1 2 3 4 5 6 →